Tisagenlecleucel

• Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending
  2025-524278-40-00 Phase IV 1 country Universitair Ziekenhuis Gent
• Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting
  2024-515328-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
• CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse Recruiting
  2023-506705-20-00 Phase II 1 country Lymphoma Academic Research Organisation
• CAR T-cell therapy long term follow-up Recruiting
  2023-508128-37-00 Phase III 12 countries Novartis Pharma Services AG
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended
  2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
• CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti… Ended
  2024-514345-11-00 Phase I/II 1 country Assistance Publique Hopitaux De Paris
• Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients Ended
  2023-508081-15-00 Phase II 8 countries Novartis Pharma AG
• Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, rela… Halted
  2024-519808-27-00 Phase I (FiH) 1 country Medical University Of Warsaw
• Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended
  2023-508127-13-00 Phase II 7 countries Novartis Pharma AG
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 Phase III 7 countries Novartis Pharma AG

Showing 1–10 of 10 trials